Skip to Main content Skip to Navigation
Journal articles

PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders

Abstract : Enzyme defects in the mitochondrial fatty acid oxidation (FAO) are a large family of inherited metabolic disease well characterized clinically and genetically, but for which pharmacological strategies remain limited. It is now well established that regulation of genes involved in mitochondrial FAO is under control of the PPAR (peroxisome proliferator activated receptor) signalling pathway, and this led us to test a possible pharmacological correction of FAO disorders by fibrates and other PPAR activators. This review presents the basic data supporting our initial hypothesis, summarizes the results obtained in cells from patients with CPT II (carnitine palmitoyltransfer-ase II) or VLCAD (very long-chain acyl-CoA dehydro-genase) deficiency, and discusses the perspectives and limits of this approach for therapy of these disorders. Abbreviations CPT II carnitine palmitoyltransferase II FALDH fatty aldehyde dehydrogenase FAO fatty acid oxidation PPAR peroxisome proliferator activated receptor RXR retinoid X receptor VLCAD very long-chain acyl-CoA dehydrogenase
Document type :
Journal articles
Complete list of metadatas

Cited literature [48 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02896250
Contributor : Fatima Djouadi <>
Submitted on : Friday, July 10, 2020 - 1:45:04 PM
Last modification on : Saturday, July 11, 2020 - 3:45:18 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

F. Djouadi, J. Bastin. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders. Journal of Inherited Metabolic Disease, Springer Verlag, 2008, 31 (2), pp.217-225. ⟨10.1007/s10545-008-0844-7⟩. ⟨inserm-02896250⟩

Share

Metrics

Record views

14